Cite
HARVARD Citation
Turajlic, S. et al. (2018). First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma. Annals of oncology. pp. 542-543. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Turajlic, S. et al. (2018). First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma. Annals of oncology. pp. 542-543. [Online].